BlossomHill Therapeutics (NASDAQ:BLSM) Now Covered by Analysts at JPMorgan Chase & Co.

Equities research analysts at JPMorgan Chase & Co. assumed coverage on shares of BlossomHill Therapeutics (NASDAQ:BLSM) in a report issued on Tuesday, MarketBeat.com reports. The brokerage set an “overweight” rating and a $28.00 price target on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 53.01% from the stock’s current price.

Several other analysts also recently commented on the stock. Wall Street Zen raised shares of BlossomHill Therapeutics to a “hold” rating in a research report on Saturday, August 15th. Guggenheim assumed coverage on shares of BlossomHill Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $30.00 target price on the stock. Finally, HC Wainwright started coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They set a “buy” rating and a $35.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $31.00.

BlossomHill Therapeutics Price Performance

NASDAQ BLSM opened at $18.30 on Tuesday. BlossomHill Therapeutics has a 12 month low of $15.25 and a 12 month high of $20.61.

Insiders Place Their Bets

In other BlossomHill Therapeutics news, General Counsel Vincent Paul Liptak bought 2,500 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was acquired at an average price of $15.80 per share, with a total value of $39,500.00. Following the transaction, the general counsel owned 109,212 shares in the company, valued at $1,725,549.60. This represents a 2.34% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director John P. Schmid bought 6,000 shares of the stock in a transaction on Monday, August 10th. The shares were bought at an average price of $16.00 per share, for a total transaction of $96,000.00. Following the purchase, the director directly owned 6,000 shares in the company, valued at approximately $96,000. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 1,573,900 shares of company stock worth $25,181,900 in the last quarter.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.